Scholarlink

<p><i>Pseudomonas aeruginosa</i> is a major opportunistic pathogen associated with high morbidity in hospitalized patients due to its intrinsic and acquired resistance mechanisms. Carbapenem resistance, often mediated by the production of carbapenemase, poses a critical therapeutic challenge worldwide. This study investigated the genomic organization, molecular diversity, and plasmid-mediated dissemination of carbapenemase genes in <i>P. aeruginosa</i> isolates from hospitals in Paraná and Santa Catarina, Brazil, and explored their correlation with phenotypic resistance profiles. Eight isolates (80%) were classified as extensively drug-resistant (XDR), showing broad resistance to β-lactams, carbapenems, and β-lactam/β-lactamase inhibitor combinations. Multi-Locus Sequence Typing revealed a heterogeneous clonal structure, with ST1560 being the predominant type (30%). Multiple β-lactamase genes were identified, including chromosomal <i>bla</i>PDC variants, <i>bla</i>OXA-50, and carbapenemase genes <i>bla</i>SPM-1, <i>bla</i>IMP-16, <i>bla</i>IMP-1, <i>bla</i>VIM-2, <i>bla</i>KPC-2, and <i>bla</i>NDM-1. Notably, 40% of isolates carried plasmid-borne carbapenemase genes, indicating a potential for horizontal gene transfer. Isolate 20,783 exhibited high resistance despite lacking additional carbapenemase genes, suggesting alternative mechanisms such as efflux or porin loss. The predominance of XDR <i>P. aeruginosa</i>,which harbors diverse carbapenemases, including plasmid-mediated determinants, underscores the complexity of antimicrobial resistance in Brazilian hospitals. The coexistence of multiple resistance mechanisms, coupled with clonal heterogeneity, highlights the urgent need for integrated genomic surveillance and targeted infection control strategies to mitigate the spread of multidrug-resistant <i>P. aeruginosa</i> in clinical settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genomic and Phenotypic Insights into Carbapenemase-Mediated Resistance and Clonal Diversity of Pseudomonas aeruginosa Clinical Isolates from Southern Brazil

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月18日

查看全文
  • Bruna Mezzomo Bejes,
  • Marcelo Ricardo Vicari,
  • Viviane Nogaroto,
  • Larissa Bail,
  • Lavinia Nery Villa Stangler Arend,
  • Keite da Silva Nogueira,
  • Sônia Alvim Veiga Pileggi,
  • Felipe Francisco Tuon,
  • Carmen Antonia Sanches Ito,
  • Luiz Ricardo Olchanheski,
  • Marcos Pileggi

摘要

Pseudomonas aeruginosa is a major opportunistic pathogen associated with high morbidity in hospitalized patients due to its intrinsic and acquired resistance mechanisms. Carbapenem resistance, often mediated by the production of carbapenemase, poses a critical therapeutic challenge worldwide. This study investigated the genomic organization, molecular diversity, and plasmid-mediated dissemination of carbapenemase genes in P. aeruginosa isolates from hospitals in Paraná and Santa Catarina, Brazil, and explored their correlation with phenotypic resistance profiles. Eight isolates (80%) were classified as extensively drug-resistant (XDR), showing broad resistance to β-lactams, carbapenems, and β-lactam/β-lactamase inhibitor combinations. Multi-Locus Sequence Typing revealed a heterogeneous clonal structure, with ST1560 being the predominant type (30%). Multiple β-lactamase genes were identified, including chromosomal blaPDC variants, blaOXA-50, and carbapenemase genes blaSPM-1, blaIMP-16, blaIMP-1, blaVIM-2, blaKPC-2, and blaNDM-1. Notably, 40% of isolates carried plasmid-borne carbapenemase genes, indicating a potential for horizontal gene transfer. Isolate 20,783 exhibited high resistance despite lacking additional carbapenemase genes, suggesting alternative mechanisms such as efflux or porin loss. The predominance of XDR P. aeruginosa,which harbors diverse carbapenemases, including plasmid-mediated determinants, underscores the complexity of antimicrobial resistance in Brazilian hospitals. The coexistence of multiple resistance mechanisms, coupled with clonal heterogeneity, highlights the urgent need for integrated genomic surveillance and targeted infection control strategies to mitigate the spread of multidrug-resistant P. aeruginosa in clinical settings.